NCT04753879
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 20 versions: 14 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 4, 2026 Show 7 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 1 word
- Trial completed
- Primary completion date changed from estimate of Jul 1, 2026 to May 7, 2026
- Enrollment target: estimated 38 to confirmed 36
- Secondary endpoint revised
- Collaborators: details revised at 1 of 1 entry
- Minor Primary and study completion dates moved earlier to Jul 1, 2026v19
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Notable Primary completion date: Dec 1, 2025 to Dec 1, 2026v17
- Minor Site contact updatedv16
Show 8 earlier versionsHide 8 earlier versions
- Minor Site contact updatedv11
- Minor Start date changed from estimate of Dec 2021 to Sep 29, 2021v9
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Notable Start date: Aug 2021 to Dec 2021
- Primary completion date: Aug 1, 2025 to Dec 1, 2025
- Study completion date: Feb 1, 2029 to Dec 1, 2029
- Notable Eligibility criteria expanded, about 11 wordsv6
- Minor Primary completion date: Aug 2025 to Aug 1, 2025
- Study completion date: Aug 2025 to Feb 1, 2029
- Notable Start date: Apr 2021 to Aug 2021
- Primary and study completion dates: Apr 2025 to Aug 2025
- Notable Primary endpoints: 1 to 2v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
The treatment period will consist of a chemotherapy phase with GAX-CI (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan) followed by a maintenance phase with pembrolizumab and olaparib. The chemotherapy phase will consist of 6 cycles of GAX-CI. Post-GAX-CI treatment, patients will receive pembrolizumab and olaparib. Maintenance phase treatment may continue up to a maximum of 2 years. Patients who had stable disease or better post-GAX-CI treatment and develop clinical or radiographic progressive disease following initiation of maintenance therapy, or those who become intolerant of treatment with either pembrolizumab or olaparib, may be retreated with GAX-CI if the PI deems that the patient will derive meaningful clinical benefit.
Drugs: Nab-paclitaxel, Gemcitabine, Cisplatin, Irinotecan, Capecitabine, Pembrolizumab, Olaparib
Sites
1 site in 1 country
- Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland, United States